Clinical Trials Browser

Epstein-Barr Virus Infections × Nivolumab × 1 year × Clear all

NCT03258567 2026-05-22

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections